Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
CMMB•Second quarter 2026 results and corporate update
- Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
- Chemomab Therapeutics Ltd - Nebokitug RA phase 2 clinical trial expected to begin in H1 2027 and read out in H1 2028
- Chemomab Therapeutics Ltd - cash, cash equivalents and short-term bank deposits were $6.7 million as of June 30, 2026
Related News
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth
INBS•
Critical Metals Corp. Provides Update On Proposed Acquisition Of European Lithium
CRML•
